MX2016007748A - Composiciones y métodos para tratar, prevenir y diagnosticar cáncer y otros trastornos proliferativos. - Google Patents
Composiciones y métodos para tratar, prevenir y diagnosticar cáncer y otros trastornos proliferativos.Info
- Publication number
- MX2016007748A MX2016007748A MX2016007748A MX2016007748A MX2016007748A MX 2016007748 A MX2016007748 A MX 2016007748A MX 2016007748 A MX2016007748 A MX 2016007748A MX 2016007748 A MX2016007748 A MX 2016007748A MX 2016007748 A MX2016007748 A MX 2016007748A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- benzylpropionamide
- dioxol
- benzo
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title 1
- SRADCMOCDMFMPS-UHFFFAOYSA-N n-[3-(1,3-benzodioxol-5-yl)-3-(2-methoxyphenyl)propyl]-n-benzylpropanamide Chemical compound C=1C=CC=CC=1CN(C(=O)CC)CCC(C=1C=C2OCOC2=CC=1)C1=CC=CC=C1OC SRADCMOCDMFMPS-UHFFFAOYSA-N 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000006439 vascular pathology Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916116P | 2013-12-13 | 2013-12-13 | |
| US201461965776P | 2014-02-06 | 2014-02-06 | |
| PCT/US2014/070221 WO2015089495A2 (en) | 2013-12-13 | 2014-12-14 | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016007748A true MX2016007748A (es) | 2017-07-28 |
Family
ID=53371974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007748A MX2016007748A (es) | 2013-12-13 | 2014-12-14 | Composiciones y métodos para tratar, prevenir y diagnosticar cáncer y otros trastornos proliferativos. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3079680A4 (enExample) |
| JP (2) | JP2017506257A (enExample) |
| CN (1) | CN107847470A (enExample) |
| AU (1) | AU2014361814A1 (enExample) |
| MX (1) | MX2016007748A (enExample) |
| WO (1) | WO2015089495A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN113106053A (zh) | 2015-04-21 | 2021-07-13 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
| EP3416661A4 (en) | 2016-02-18 | 2020-03-04 | Enlivex Therapeutics Ltd. | COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER |
| LU100900B1 (de) * | 2018-08-10 | 2020-02-17 | Thomas Melchior Homann | Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen |
| EP3760614B8 (en) * | 2019-07-02 | 2022-04-27 | Universität Heidelberg | Chemical inhibitors of id proteins for the treatment of cancer and other diseases |
| JP2022550589A (ja) * | 2019-10-01 | 2022-12-02 | メモリアル スローン ケタリング キャンサー センター | Ｉｄタンパク質の小分子阻害剤 |
| CN113627763B (zh) * | 2021-07-30 | 2023-12-01 | 厦门大学 | 一种风险量化评估模型建立方法 |
| CN114480490A (zh) * | 2021-12-31 | 2022-05-13 | 四川省医学科学院·四川省人民医院 | 一种构建视网膜新生血管性疾病动物模型的方法 |
| CN115487358B (zh) * | 2022-08-05 | 2023-05-30 | 核工业四一六医院 | 一种用于软骨组织修复的凝胶复合支架及制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8138356B2 (en) * | 2007-10-16 | 2012-03-20 | Angiogeney, Inc. | Chemical inhibitors of inhibitors of differentiation |
| WO2012000036A1 (en) * | 2010-06-30 | 2012-01-05 | Garvan Institute Of Medical Research | Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1 |
| US9745288B2 (en) * | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
-
2014
- 2014-12-14 WO PCT/US2014/070221 patent/WO2015089495A2/en not_active Ceased
- 2014-12-14 EP EP14870415.8A patent/EP3079680A4/en not_active Withdrawn
- 2014-12-14 AU AU2014361814A patent/AU2014361814A1/en not_active Abandoned
- 2014-12-14 CN CN201480075495.2A patent/CN107847470A/zh active Pending
- 2014-12-14 JP JP2016558543A patent/JP2017506257A/ja active Pending
- 2014-12-14 MX MX2016007748A patent/MX2016007748A/es unknown
-
2019
- 2019-09-06 JP JP2019162598A patent/JP2019203028A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015089495A2 (en) | 2015-06-18 |
| WO2015089495A3 (en) | 2015-11-12 |
| EP3079680A2 (en) | 2016-10-19 |
| JP2019203028A (ja) | 2019-11-28 |
| EP3079680A4 (en) | 2017-11-22 |
| AU2014361814A1 (en) | 2016-07-28 |
| JP2017506257A (ja) | 2017-03-02 |
| CN107847470A (zh) | 2018-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016007748A (es) | Composiciones y métodos para tratar, prevenir y diagnosticar cáncer y otros trastornos proliferativos. | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| MY171486A (en) | Atx modulating agents | |
| SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| EA201391416A1 (ru) | Новые соединения в качестве модуляторов протеинкиназ | |
| MX387394B (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| WO2017096309A8 (en) | Methods of treatment of malignancies | |
| EA201790267A1 (ru) | Новые модуляторы киназ | |
| PH12015501370A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| UA116774C2 (uk) | Інгібітори серин/треонінкінази | |
| CL2012000592A1 (es) | Compuestos derivados de fenoxi o fenil-tieno[3,2-b]piridina, inhibidores de tirosina quinasas; composicion farmaceutica; y su uso en el tratamiento de cancer colorrectal, de pulmon, hematologico, de higado, mama, en retinopatia diabetica, degeneracion macular, glaucoma, psoriasis, diabetes, enfermedades neurodegenerativas, entre otras. | |
| MX2014013090A (es) | Derivados de pirrolotriazinona. | |
| MX362939B (es) | Derivados de (aza-)isoquinolinona. | |
| PH12014501829A1 (en) | Bicyclic pyrazinone derivatives | |
| EA201491520A1 (ru) | НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ | |
| EP4353319A3 (en) | Methods of adoptive cell therapy | |
| MX349550B (es) | 1,7-diazacarbazoles y metodos de uso. | |
| EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
| MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
| MX377304B (es) | Derivados de piperazina como moduladores de los receptores x del hígado. | |
| MX357888B (es) | Sales basicas de adicion de nitroxolina y usos de las mismas. | |
| PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers |